| |
AS (n = 15)
|
RA (n = 17)
|
p-value
|
|---|
|
Age (years, mean ± SD)
|
32.9 ± 9.6
|
56.2 ± 10.4
|
<0.0001
|
|
Sex (male, n (%))
|
12 (80.0 %)
|
2 (11.8 %)
|
<0.0001
|
|
ESR (mm/h, mean ± SD)
|
53.7 ± 35.5
|
56.5 ± 31.3
|
NS
|
|
CRP (mg/dL, mean ± SD)
|
3.5 ± 3.5
|
2.9 ± 3.4
|
NS
|
|
Disease duration (years, mean ± SD)
|
5.2 ± 6.1
|
6.1 ± 6.3
|
NS
|
|
Eye involvement (n (%))
|
5 (33.3 %)
|
N/A
| |
|
HLA-B27 positive (n (%))
|
13 (86.7 %)
|
N/A
| |
|
BASDAI (mean ± SD)
|
4.3 ± 2.3
|
N/A
| |
|
mSASSS (mean ± SD)
|
15.8 ± 16.7
|
N/A
| |
|
Sacroiliitis grading (n (%))
|
|
Grade 2
|
3 (20.0 %)
|
N/A
| |
|
Grade 3
|
9 (60.0 %)
|
N/A
|
|
Grade 4
|
3 (20.0 %)
|
N/A
|
|
Current medications (n (%))
|
|
MTX
|
7 (46.7 %)
|
14 (82.4 %)
|
0.062
|
|
SSZ
|
8 (53.3 %)
|
1 (5.9 %)
|
0.005
|
|
TNFi
|
3 (20 %)
|
1 (5.9 %)
|
0.319
|
|
NSAID
|
13 (86.7 %)
|
16 (94.1 %)
|
0.589
|
-
AS ankylosing spondylitis, BASDAI bath ankylosing spondylitis disease activity index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MTX methotrexate, N/A not available, NS not significant, NSAID nonsteroidal anti-inflammatory drug, RA rheumatoid arthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor
